GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vireo Growth Inc (OTCPK:VREOF) » Definitions » Sloan Ratio %

VREOF (Vireo Growth) Sloan Ratio % : -3.58% (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Vireo Growth Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Vireo Growth's Sloan Ratio for the quarter that ended in Sep. 2024 was -3.58%.

As of Sep. 2024, Vireo Growth has a Sloan Ratio of -3.58%, indicating the company is in the safe zone and there is no funny business with accruals.


Vireo Growth Sloan Ratio % Historical Data

The historical data trend for Vireo Growth's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vireo Growth Sloan Ratio % Chart

Vireo Growth Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.95 -24.31 2.42 -11.79 -11.52

Vireo Growth Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.69 -11.52 -11.36 -5.98 -3.58

Competitive Comparison of Vireo Growth's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vireo Growth's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Vireo Growth's Sloan Ratio % falls into.



Vireo Growth Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Vireo Growth's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-25.547--0.966
--3.475)/183.264
=-11.52%

Vireo Growth's Sloan Ratio for the quarter that ended in Sep. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2024 )
=(-16.888--4.251
--5.695)/193.869
=-3.58%

Vireo Growth's Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was -4.583 (Dec. 2023 ) + -6.711 (Mar. 2024 ) + -0.668 (Jun. 2024 ) + -4.926 (Sep. 2024 ) = $-16.89 Mil.
Vireo Growth's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2024 was -0.46 (Dec. 2023 ) + -1.19 (Mar. 2024 ) + -0.01 (Jun. 2024 ) + -2.591 (Sep. 2024 ) = $-4.25 Mil.
Vireo Growth's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 was -0.171 (Dec. 2023 ) + -1.049 (Mar. 2024 ) + -3.189 (Jun. 2024 ) + -1.286 (Sep. 2024 ) = $-5.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vireo Growth  (OTCPK:VREOF) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2024, Vireo Growth has a Sloan Ratio of -3.58%, indicating the company is in the safe zone and there is no funny business with accruals.


Vireo Growth Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Vireo Growth's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vireo Growth Business Description

Traded in Other Exchanges
Address
207 South 9th Street, Minneapolis, Minneapolis, MN, USA, 55402
Vireo Growth Inc is a cannabis company whose mission is to provide safe access, quality products, and value to its customers while supporting its local communities through active participation and restorative justice programs.
Executives
Chicago Atlantic Credit Opportunities, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Manager, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Gp Holdings, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Group, Lp 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Group Gp, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Advisers, Llc 10 percent owner 420 NORTH WABASH AVENUE, SUITE 500, CHICAGO IL 60611
Joshua Rosen director 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Victor E. Mancebo director C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Christian Gonzales Ocasio officer: Chief Operating Officer C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Amber Holly Shimpa director, officer: Chief Administrative Officer C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Patrick Peters officer: EVP of Retail C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
J Michael Schroeder officer: General Counsel & CCO 3680 VICTORA STREET N, SHOREVIEW MN 55126
John Andrew Heller officer: Chief Financial Officer C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Ross Michael Hussey director C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Judd Theodore Nordquist director C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402